The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Antimicrobial Resistance Management — Stewardship, ESBL/CRE Pathogens, and Novel Agents

Comprehensive approach to antimicrobial resistance including ESBL Enterobacterales, carbapenem-resistant organisms (CRE/CRAB), MRSA, VRE, and multidrug-resistant Pseudomonas, encompassing antimicrobial stewardship, infection prevention, and modern targeted therapeutics including novel beta-lactam/beta-lactamase inhibitor combinations.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Internal Medicine department. Book Appointment →

What is Antimicrobial Resistance Management — Stewardship, ESBL/CRE Pathogens, and Novel Agents?

Antimicrobial resistance arises through multiple mechanisms including production of inactivating enzymes (beta-lactamases, aminoglycoside-modifying enzymes), target site modification (penicillin-binding proteins in MRSA, ribosomal mutations), efflux pumps, decreased outer membrane permeability, and biofilm formation. Resistance genes spread through horizontal transmission via plasmids, transposons, and integrons, accelerating dissemination across species and geographic regions. The WHO has identified priority pathogens including critical (carbapenem-resistant Acinetobacter, Pseudomonas, Enterobacterales), high (vancomycin-resistant Enterococcus, methicillin-resistant Staphylococcus aureus), and medium (Streptococcus pneumoniae, Haemophilus influenzae) priority categories.

Major resistant pathogens encountered clinically include extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales (E. coli, Klebsiella, Proteus), conferring resistance to third-generation cephalosporins; carbapenem-resistant Enterobacterales (CRE) producing KPC, NDM, OXA-48, VIM, or IMP carbapenemases; carbapenem-resistant Acinetobacter baumannii (CRAB); multidrug-resistant Pseudomonas aeruginosa; methicillin-resistant Staphylococcus aureus (MRSA) including community-associated and hospital-associated strains; vancomycin-resistant enterococci (VRE) particularly E. faecium; and emerging resistance in Mycobacterium tuberculosis (MDR-TB, XDR-TB) and Neisseria gonorrhoeae.

Modern management combines empirical antibiotic selection guided by local antibiograms and risk stratification, rapid molecular diagnostic testing (multiplex PCR for resistance genes, MALDI-TOF identification, syndromic panels), and targeted therapy with novel agents. For ESBL infections, carbapenems remain mainstay though oral options exist for cystitis. For CRE, novel agents include ceftazidime-avibactam (active against KPC, OXA-48), meropenem-vaborbactam (KPC), imipenem-cilastatin-relebactam (KPC, OXA-48), and cefiderocol (siderophore cephalosporin active against most carbapenemases including NDM and metallo-beta-lactamases). For MDR Pseudomonas, ceftolozane-tazobactam is preferred. Novel agents for MRSA include lipoglycopeptides (dalbavancin, oritavancin) and ceftaroline. Antimicrobial stewardship programs reducing inappropriate prescribing through prospective audit, formulary restriction, and education are essential. Infection prevention through hand hygiene, contact precautions, environmental cleaning, and active surveillance reduces transmission.

Symptoms

Failure of empirical antibiotic therapy
Persistent infection despite appropriate-spectrum agents
Recurrent infection after initial response
Severe infection in patient with healthcare exposure
Resistant organism on culture and susceptibility
Travel history with healthcare exposure abroad
Outbreak in healthcare facility or community

Risk Factors

Recent antibiotic use (especially broad-spectrum)
Healthcare exposure (hospitalization, dialysis, long-term care)
Prior infection or colonization with resistant organism
International travel especially to high-resistance regions
Immunosuppression and complex comorbidity
Indwelling devices (catheters, ventilators)
Prolonged ICU stay

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Failure of empirical antibiotic therapy after 48-72 hours
  • Severe infection in patient with healthcare exposure
  • Recent travel with serious infection
  • Recurrent UTI or other infection unresponsive to standard therapy
  • Outbreak suspicion in healthcare or community setting
  • Need for prolonged antibiotic course (>2 weeks)
  • Complicated infection with multidrug-resistant organism

Treatment Methods

01
Targeted therapy based on culture and susceptibility testing
02
Novel agents for CRE: ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol
03
Ceftolozane-tazobactam for MDR Pseudomonas aeruginosa
04
Lipoglycopeptides (dalbavancin) and ceftaroline for resistant MRSA
05
Antimicrobial stewardship: prospective audit, education, formulary management
06
Infection prevention: hand hygiene, contact precautions, environmental cleaning
07
Infectious disease consultation for complex resistant infections

Which Department to Visit?

You can visit our Enfeksiyon Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Enfeksiyon Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Flu (Influenza)

Enfeksiyon Hastalıkları

Influenza is a seasonal contagious respiratory disease caused by influenza viruses; it presents with high fever, muscle pain, and severe fatigue.

COVID-19

Enfeksiyon Hastalıkları

COVID-19 is a contagious disease caused by the SARS-CoV-2 coronavirus with a wide clinical spectrum ranging from asymptomatic to severe pneumonia.

Upper Respiratory Tract Infection

Enfeksiyon Hastalıkları

Upper respiratory tract infections are diseases that include common cold, pharyngitis, sinusitis, and laryngitis, often of viral origin and self-limited.

Urinary Tract Infection

Enfeksiyon Hastalıkları

Urinary tract infections are common bacterial infections most often caused by Escherichia coli, presenting with burning and frequent urination.

Hepatitis A (HAV)

Enfeksiyon Hastalıkları

Hepatitis A is an acute, self-limited liver infection transmitted via the fecal-oral route causing acute hepatitis without chronicity; supportive care suffices in most cases, while vaccination prevents outbreaks and post-exposure prophylaxis within 2 weeks is effective.

Hepatitis B

Enfeksiyon Hastalıkları

Hepatitis B is a contagious infection caused by HBV virus transmitted via blood, sexual intercourse, and mother-to-child, that can become chronic and progress to cirrhosis and liver cancer.

Hepatitis C

Enfeksiyon Hastalıkları

Hepatitis C is a liver disease caused by HCV virus transmitted mainly by blood; the rate of chronicity is high, but cure is possible with new antiviral drugs.

HIV/AIDS Information

Enfeksiyon Hastalıkları

HIV is a virus that targets the immune system; if untreated, it progresses to AIDS. With modern antiretroviral therapy, HIV-positive individuals can lead healthy, long lives.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.